U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H21FN2O.C2H2O4
Molecular Weight 414.4268
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESCITALOPRAM OXALATE

SMILES

OC(=O)C(O)=O.CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3

InChI

InChIKey=KTGRHKOEFSJQNS-BDQAORGHSA-N
InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)/t20-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C2H2O4
Molecular Weight 90.0349
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H21FN2O
Molecular Weight 324.3919
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Escitalopram, also known by the brand names Lexapro and Cipralex among others, is an antidepressant. The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. LEXAPRO (escitalopram) is indicated for the treatment of major depressive disorder and generalized anxiety disorder .

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LEXAPRO

Approved Use

INDICATIONS & USAGE Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for: Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12 to 17 years (1.1) Acute Treatment of Generalized Anxiety Disorder (GAD) in adults (1.2) Escitalopram tablets USP are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age.

Launch Date

1.02928318E12
Primary
LEXAPRO

Approved Use

Lexapro® is a selective serotonin reuptake inhibitor (SSRI) indicated for: Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12-17 years (1.1) Acute Treatment of Generalized Anxiety Disorder (GAD) in adults (1.2)

Launch Date

1.02928318E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
63.4 nM
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
198.4 nM
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
58.6 nM
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
58 nM
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1109 nM × h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3391 nM × h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1102 nM × h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1964 nM × h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29 h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
32.5 h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26.6 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
26.7 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
44%
ESCITALOPRAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Disc. AE: Coma, Dizziness...
AEs leading to
discontinuation/dose reduction:
Coma (grade 3-4, 1 patient)
Dizziness (grade 1-2, 2 patients)
Restlessness (grade 1-2, 2 patients)
Agitation (grade 3-4, 4 patients)
Convulsion (grade 3-4, 1 patient)
Tremor (grade 1-2, 8 patients)
Mydriasis (grade 1-2, 3 patients)
Tachycardia (grade 1-2, 7 patients)
Change in ECG (grade 1-2, 4 patients)
Change in ECG (grade 3-4, 1 patient)
Nausea (grade 1-2, 4 patients)
Vomiting (grade 1-2, 8 patients)
Vomiting (grade 3-4, 1 patient)
Intestinal atony (grade 3-4, 1 patient)
Urinary retention (grade 3-4, 1 patient)
Somnolence (grade 1-2, 25 patients)
Sources:
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Disc. AE: Clonus, Clonus...
AEs leading to
discontinuation/dose reduction:
Clonus (12 patients)
Clonus (2 patients)
Hyperreflexia (21 patient)
Myoclonus (3 patients)
Eyelid myoclonus (2 patients)
Hunter's syndrome (7 patients)
Sources:
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Disc. AE: Clonus, Hyperreflexia...
AEs leading to
discontinuation/dose reduction:
Clonus (3 patients)
Hyperreflexia (9 patients)
Eyelid myoclonus (2 patients)
Hunter's syndrome (1 patient)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 46.2 years
n = 4185
Health Status: unhealthy
Condition: Psychiatric diagnoses
Age Group: 46.2 years
Sex: M+F
Population Size: 4185
Sources:
Disc. AE: Coronary heart disease...
AEs leading to
discontinuation/dose reduction:
Coronary heart disease (10.7%)
Sources:
33.8 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 33.8 mg, 1 times / day
Route: oral
Route: steady
Dose: 33.8 mg, 1 times / day
Sources:
unhealthy, adult
n = 64
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 64
Sources:
Other AEs: Dry mouth, Sexual desire decreased...
Other AEs:
Dry mouth (8 patients)
Sexual desire decreased (21 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness grade 1-2, 2 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Restlessness grade 1-2, 2 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Somnolence grade 1-2, 25 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Mydriasis grade 1-2, 3 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Change in ECG grade 1-2, 4 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Nausea grade 1-2, 4 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Tachycardia grade 1-2, 7 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Tremor grade 1-2, 8 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Vomiting grade 1-2, 8 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Change in ECG grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Coma grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Convulsion grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Intestinal atony grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Urinary retention grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Vomiting grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Agitation grade 3-4, 4 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Clonus 12 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Clonus 2 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Eyelid myoclonus 2 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Hyperreflexia 21 patient
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Myoclonus 3 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Hunter's syndrome 7 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Hunter's syndrome 1 patient
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Eyelid myoclonus 2 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Clonus 3 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Hyperreflexia 9 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Coronary heart disease 10.7%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 46.2 years
n = 4185
Health Status: unhealthy
Condition: Psychiatric diagnoses
Age Group: 46.2 years
Sex: M+F
Population Size: 4185
Sources:
Sexual desire decreased 21 patient
33.8 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 33.8 mg, 1 times / day
Route: oral
Route: steady
Dose: 33.8 mg, 1 times / day
Sources:
unhealthy, adult
n = 64
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 64
Sources:
Dry mouth 8 patients
33.8 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 33.8 mg, 1 times / day
Route: oral
Route: steady
Dose: 33.8 mg, 1 times / day
Sources:
unhealthy, adult
n = 64
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 64
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
no
yes [IC50 70 uM]
yes (co-administration study)
Comment: coadministration of metoprolol with escitalopram increased concetrations of metoprolol (p50 of clinical pharmacology review)
Page: 70.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes [Km 29 uM]
yes (co-administration study)
Comment: coadministration of escitalopram with desipramine resulted in a 50% increase in desipramine concentraitons
Page: 70.0
yes [Km 588 uM]
yes [Km 69 uM]
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
2002 Apr
Gateways to clinical trials.
2002 Dec
[Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine].
2002 Jul-Aug
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
2002 May
[Who does need Cipralex and why?].
2002 May 16
Escitalopram.
2002 Oct
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.
2002 Oct
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.
2003
An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.
2003 Apr
Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry.
2003 Dec
R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety.
2003 Jul
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
2003 Jul
Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
2003 Jun
R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
2003 Sep
A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
2004
New formulations of existing antidepressants: advantages in the management of depression.
2004
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
2004
Spotlight on the pharmacoeconomics of escitalopram in depression.
2004
Gateways to clinical trials.
2004 Dec
A case of hyponatremia associated with escitalopram.
2004 Dec
Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups.
2004 Feb
Gateways to clinical trials.
2004 Jan-Feb
Gateways to clinical trials.
2004 Jul-Aug
[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
2004 Mar-Apr
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
2004 May
Venous thromboembolism and escitalopram.
2004 Nov-Dec
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
2004 Sep
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
2005 Jan
Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV.
2005 Jan
Evidence-based pharmacotherapy of Generalized Anxiety Disorder.
2005 Jun
The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
2005 Mar
Escitalopram and suicidality in adult depression and anxiety.
2005 May
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
2005 May
Patents

Sample Use Guides

Lexapro (escitalopram) should generally be administered once daily, morning or evening with or without food. Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily
Route of Administration: Oral
Escitalopram blocked human hERG currents expressed in human embryonic kidney cells in a concentration-dependent manner with an IC50 value of 2.6 uM
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:20:57 UTC 2023
Edited
by admin
on Wed Jul 05 23:20:57 UTC 2023
Record UNII
5U85DBW7LO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESCITALOPRAM OXALATE
JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
ESCITALOPRAM OXALATE [USAN]
Common Name English
LU-26-054-O
Code English
S-(+)-1-(3-(DIMETHYLAMINO)PROPYL)-1-(P-FLUOROPHENYL)-5-PHTHALANCARBONITRILE OXALATE
Common Name English
LEXAPRO
Brand Name English
LU-26-054-0
Code English
ESCITALOPRAM (AS OXALATE)
Common Name English
ESCITALOPRAM OXALATE [EP MONOGRAPH]
Common Name English
ESCITALOPRAM OXALATE [MART.]
Common Name English
ESCITALOPRAM OXALATE [VANDF]
Common Name English
ESCITALOPRAM OXALATE [MI]
Common Name English
LU 26-054-0
Code English
ESCITALOPRAM OXALATE [USP-RS]
Common Name English
CITALOPRAM OXALATE, (S)-
Common Name English
ESCITALOPRAM OXALATE [USP MONOGRAPH]
Common Name English
ESCITALOPRAM OXALATE [JAN]
Common Name English
Escitalopram oxalate [WHO-DD]
Common Name English
ESCITALOPRAM OXALATE [ORANGE BOOK]
Common Name English
NSC-758934
Code English
S-(+)-5-ISOBENZOFURANCARBONITRILE, 1-(3-(DIMETHYLAMINO)PROPYL)-1-(4-FLUOROPHENYL)-1,3-DIHYDRO-, OXALATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
NCI_THESAURUS C94725
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
Code System Code Type Description
DRUG BANK
DBSALT002455
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
DAILYMED
5U85DBW7LO
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
RXCUI
353108
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY RxNorm
NSC
758934
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
USAN
MM-73
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
FDA UNII
5U85DBW7LO
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
CAS
219861-08-2
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
ChEMBL
CHEMBL1508
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
SMS_ID
100000090506
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
NCI_THESAURUS
C47518
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
EVMPD
SUB16426MIG
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
EPA CompTox
DTXSID1046003
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
PUBCHEM
146571
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
RS_ITEM_NUM
1249406
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY
MERCK INDEX
M3587
Created by admin on Wed Jul 05 23:20:57 UTC 2023 , Edited by admin on Wed Jul 05 23:20:57 UTC 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
RACEMATE -> ENANTIOMER
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY